Comparison of meropenem-vaborbactam with ceftazidime-avibactam in the treatment of carbapenem-resistant Enterobacterales infections
Luca Mezzadri(University of Milano-Bicocca), Paolo Bonfanti(University of California San Diego), Paolo Maggi(Università degli Studi di Enna Kore), Goffredo Angioni(Santissima Trinità), Giuseppe Vittorio De Socio(University of Perugia), Elena Ricci(Mario Negri Institute for Pharmacological Research), Alessandra Bandera(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Letizia Attala(Ospedale Santa Maria Annunziata), Marco Merli(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Giordano Madeddu(University of Sassari), Antonio Mastroianni(Azienda Ospedaliera di Cosenza), Alessandro Pandolfo(Alessandro Manzoni Hospital), Michele Bartoletti(University of Bologna), Marianna Rossi(Azienda Ospedaliera San Gerardo), Katia Falasca(University of Chieti-Pescara), Giovanni Cenderello(Ospedale di Sanremo), Matteo Faltoni(University of Modena and Reggio Emilia)
Cited by 4
Related Papers
Tocilizumab in patients with severe COVID-19: a retrospective cohort study
|The Lancet Rheumatology|2020|998
Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide
|Gastroenterology|2018|513
Hospital-Acquired Infections in Critically Ill Patients With COVID-19
|CHEST Journal|2021|404
High rates of 30-day mortality in patients with cirrhosis and COVID-19
|Journal of Hepatology|2020|394